U.S. markets closed

Aspen Pharmacare Holdings Limited (APN.JO)

Johannesburg - Johannesburg Delayed Price. Currency in ZAc
Add to watchlist
23,622.00+597.00 (+2.59%)
At close: 5:06PM SAST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23,025.00
Open22,656.00
Bid23,310.00 x 0
Ask23,990.00 x 0
Day's Range22,424.00 - 23,716.00
52 Week Range10,298.00 - 23,716.00
Volume3,826,088
Avg. Volume1,034,493
Market Cap10.76T
Beta (5Y Monthly)0.72
PE Ratio (TTM)2,243.73
EPS (TTM)10.53
Earnings DateSep 01, 2021
Forward Dividend & Yield2.62 (1.11%)
Ex-Dividend DateSep 21, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      UPDATE 2-S.Africa's Aspen seeks licence for J&J COVID shot as EU shipments halted

      Aspen Pharmacare said on Thursday it was in talks to make Johnson & Johnson's coronavirus shot under licence in South Africa, at what would be the continent's first major independent distribution base for a global vaccine against COVID-19. News of the talks coincided with the suspension of heavily criticised shipments to Europe from Africa of the same shot, which is already being made under contract and packaged by Aspen but distributed by J&J.

    • Reuters

      Aspen eyes Serum Institute model as it seeks licence to make J&J vaccine

      South Africa's Aspen Pharmacare wants to model itself on India's Serum Institute by getting a licence to manufacture Johnson & Johnson's (J&J) COVID-19 vaccine, Aspen Chief Executive Stephen Saad said on Thursday.

    • Reuters

      Aspen in talks with J&J to produce and market COVID-19 vaccine

      South Africa's Aspen Pharmacare is in talks with Johnson & Johnson over a licence to manufacture, market and sell COVID-19 vaccines in South Africa, according to a company presentation uploaded on its website on Thursday morning. "If successful with a licence, Aspen will not only have manufacturing but will also have the rights to its own branded product," the presentation said.